Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.

320.86 0.34 −0.11%
Market cap
$12.7B
P/E
78.4×
Fwd P/E
63.5×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a

Penumbra, Inc. (PEN) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Penumbra, Inc. (PEN) trades at a P/E ratio of 78.4×. Over the past ten years it has ranged from 0.0× (March 2023) to 2,127× (June 2023); the current reading is higher than 40% of that period. That is above the Medical Devices industry median of 23.2× and above the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 68.0× (89.40%)
FY2024 642× 516.22%
FY2023 104× —
FY2022 0.0× —
FY2021 1,915× —
FY2020 0.0× —
FY2019 117× (81.76%)
FY2018 643× (9.52%)
FY2017 711× 438.39%
FY2016 132× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 77.2× 2.97%
Mar 2026 75.0× 10.20%
Dec 2025 68.0× 13.87%
Sep 2025 59.7× (10.83%)
42 more quarters

Against its own ten years

Low 0.0× High 2,127×
Ten-year median 127×
Current reading's percentile 15

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on PEN